CN Patent

CN104983733B — Nicardipine在制备抗肺癌产品中的应用

Assigned to Shanghai Jiao Tong University · Expires 2019-01-08 · 7y expired

What this patent protects

本发明公开了Nicardipine在制备抗肺癌产品中的应用。本发明提供了Nicardipine在制备治疗非小细胞肺癌产品中的应用。本发明的实验证明，本发明对FDA,CFDA已获批准的药物Nicardipine进行肿瘤药物重定位，根据肿瘤不同的细胞系(组织类型)以及突变位点对适应症不是抗肿瘤的药物进行筛选，发现Nicardipine抗小细胞肺癌和/或非小细胞肺癌这种新用途，实现旧药新用。

USPTO Abstract

本发明公开了Nicardipine在制备抗肺癌产品中的应用。本发明提供了Nicardipine在制备治疗非小细胞肺癌产品中的应用。本发明的实验证明，本发明对FDA,CFDA已获批准的药物Nicardipine进行肿瘤药物重定位，根据肿瘤不同的细胞系(组织类型)以及突变位点对适应症不是抗肿瘤的药物进行筛选，发现Nicardipine抗小细胞肺癌和/或非小细胞肺癌这种新用途，实现旧药新用。

Drugs covered by this patent

nicardipine-hydrochloride (NICARDIPINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN104983733B
Jurisdiction: CN
Classification: —
Expires: 2019-01-08
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Jiao Tong University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.